Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 690721, 10 pages
Research Article

Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines

1Biochemistry, Biochemical Analysis & Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece
2Department of Anatomy/Histology/Embryology, Unit of Bone and Soft Tissue Studies, School of Medicine, University of Patras, 26500 Patras, Greece
3Hematology Division, Department of Internal Medicine, University Hospital of Patras, 26500 Patras, Greece
4School of Health Professions, Department of Medical Laboratories, Technological Educational Institute of Larissa, 41110 Larissa, Greece

Received 30 April 2015; Revised 10 July 2015; Accepted 14 July 2015

Academic Editor: Martin Götte

Copyright © 2015 Angeliki Korpetinou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In the present pilot study, we examined the presence of serglycin in lung, breast, prostate, and colon cancer and evaluated its expression in cell lines and tissues. We found that serglycin was expressed and constitutively secreted in culture medium in high levels in more aggressive cancer cells. It is worth noticing that aggressive cancer cells that harbor KRAS or EGFR mutations secreted serglycin constitutively in elevated levels. Furthermore, we detected the transcription of an alternative splice variant of serglycin lacking exon 2 in specific cell lines. In a limited number of tissue samples analyzed, serglycin was detected in normal epithelium but was also expressed in higher levels in advanced grade tumors as shown by immunohistochemistry. Serglycin staining was diffuse, granular, and mainly cytoplasmic. In some cancer cells serglycin also exhibited membrane and/or nuclear immunolocalization. Interestingly, the stromal cells of the reactive tumor stroma were positive for serglycin, suggesting an enhanced biosynthesis for this proteoglycan in activated tumor microenvironment. Our study investigated for first time the distribution of serglycin in normal epithelial and cancerous lesions in most common cancer types. The elevated levels of serglycin in aggressive cancer and stromal cells may suggest a key role for serglycin in disease progression.